AMPH Amphastar P

$25.36

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 11/21/2025

About Amphastar P

Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company is headquartered in Rancho Cucamonga, California.

Website: https://www.amphastar.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1297184
Address
11570 SIXTH STREET, RANCHO CUCAMONGA, CA, US
Valuation
Market Cap
$1.11B
P/E Ratio
7.63
PEG Ratio
2.77
Price to Book
1.51
Performance
EPS
$3.06
Dividend Yield
—
Profit Margin
21.80%
ROE
23.30%
Technicals
50D MA
$28.31
200D MA
$39.69
52W High
$53.95
52W Low
$22.64
Fundamentals
Shares Outstanding
48M
Target Price
$39.00
Beta
0.79

AMPH EPS Estimates vs Actual

● Estimated
● Actual

AMPH News & Sentiment

Nov 06, 2025 • Zacks Commentary NEUTRAL
Amphastar Pharmaceuticals ( AMPH ) Q3 Earnings and Revenues Top Estimates
Amphastar (AMPH) delivered earnings and revenue surprises of +20.78% and +3.96%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Nov 04, 2025 • Zacks Commentary NEUTRAL
Personalis ( PSNL ) Reports Q3 Loss, Tops Revenue Estimates
Personalis (PSNL) delivered earnings and revenue surprises of +14.29% and +5.80%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Oct 30, 2025 • Zacks Commentary SOMEWHAT-BULLISH
CRMD vs. TBPH: Which Small-Cap Biotech Stock Is the Better Buy?
CorMedix and Theravance take sharply different routes to small-cap biotech growth - one fueled by sales traction, the other by pipeline promise.
Oct 30, 2025 • Zacks Commentary NEUTRAL
Analysts Estimate Amphastar Pharmaceuticals ( AMPH ) to Report a Decline in Earnings: What to Look Out for
Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Oct 28, 2025 • Zacks Commentary BULLISH
Should Investors Buy CorMedix Stock Ahead of Q3 Earnings Report?
CRMD's Q3 momentum, fueled by DefenCath's strong uptake and Melinta's revenue boost, positions the stock for continued growth.
Oct 20, 2025 • Zacks Commentary SOMEWHAT-BULLISH
How Will DefenCath Aid CRMD's Top Line in the Upcoming Q3 Results?
CorMedix's DefenCath, the first FDA-approved antimicrobial catheter lock, is expected to drive Q3 growth as new Melinta drugs add to momentum.
Sentiment Snapshot

Average Sentiment Score:

0.103
50 articles with scored sentiment

Overall Sentiment:

Neutral

AMPH Reported Earnings

Aug 07, 2025
Jun 30, 2025 (Pre market)
0.11 Surprise
  • Reported EPS: $0.85
  • Estimate: $0.74
  • Whisper: —
  • Surprise %: 14.9%
May 07, 2025
Mar 31, 2025 (Post market)
0.05 Surprise
  • Reported EPS: $0.74
  • Estimate: $0.69
  • Whisper: —
  • Surprise %: 7.6%
Feb 27, 2025
Dec 31, 2024 (Post market)
-0.02 Surprise
  • Reported EPS: $0.92
  • Estimate: $0.94
  • Whisper: —
  • Surprise %: -1.9%
Nov 06, 2024
Sep 30, 2024 (Post market)
-0.04 Surprise
  • Reported EPS: $0.96
  • Estimate: $1.00
  • Whisper: —
  • Surprise %: -4.0%
Aug 07, 2024
Jun 30, 2024 (Post market)
0.17 Surprise
  • Reported EPS: $0.94
  • Estimate: $0.77
  • Whisper: —
  • Surprise %: 22.1%
May 08, 2024
Mar 31, 2024 (Pre market)
0.08 Surprise
  • Reported EPS: $1.04
  • Estimate: $0.96
  • Whisper: —
  • Surprise %: 8.3%
Feb 28, 2024
Dec 31, 2023 (Post market)
-0.05 Surprise
  • Reported EPS: $0.88
  • Estimate: $0.93
  • Whisper: —
  • Surprise %: -5.4%
Nov 08, 2023
Sep 30, 2023 (Post market)
0.46 Surprise
  • Reported EPS: $1.15
  • Estimate: $0.69
  • Whisper: —
  • Surprise %: 66.7%
Aug 08, 2023
Jun 30, 2023 (Post market)
0.09 Surprise
  • Reported EPS: $0.65
  • Estimate: $0.56
  • Whisper: —
  • Surprise %: 16.1%

Financials